Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers

SIMPLE SUMMARY: Men with certain genetic differences are at much higher risks of developing metastatic and lethal prostate cancer. With the recent introduction of a new class of medications specifically targeted to these gene repair pathways (PARP inhibitors), it is critical to review the state of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Roderick, Herrera-Caceres, Jaime, Kenk, Miran, Fleshner, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870148/
https://www.ncbi.nlm.nih.gov/pubmed/35205755
http://dx.doi.org/10.3390/cancers14041004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870148/
https://www.ncbi.nlm.nih.gov/pubmed/35205755
http://dx.doi.org/10.3390/cancers14041004

Ejemplares similares